Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

Core Viewpoint - Aptose Biosciences Inc. has entered into a common share purchase agreement with an institutional investor to raise capital for its clinical-stage oncology developments, particularly focusing on its lead drug tuspetinib for treating acute myeloid leukemia (AML) [1][5]. Group 1: Financing Agreements - The Committed Equity Facility agreement allows Aptose to sell and issue up to $25 million of its common shares over 24 months, subject to certain conditions and regulatory limitations [2]. - Aptose has also established a sales agreement for "at-the-market" (ATM) distributions on Nasdaq, with an aggregate offering price of up to$1 million [3]. Group 2: Company Overview - Aptose is a clinical-stage biotechnology company focused on developing precision medicines for unmet medical needs in oncology, with an emphasis on hematology [5]. - The company's lead product, tuspetinib (TUS), is being developed as a frontline triplet therapy for newly diagnosed AML and has shown efficacy as both a monotherapy and in combination therapy for relapsed or refractory AML [5].